AlloVir Stock
A cell therapy firm focused on developing off-the-shelf T-cell therapies for viral diseases. Its proprietary VST platform targets 11 viruses, with posoleucel leading in treating six. The firm is dedicated to addressing the urgent need for treatments and works to prevent and treat severe viral diseases where limited options exist.
Founded: 2013
For more AlloVir stock information, or to buy or sell private shares, sign up for a MicroVentures account.
AlloVir Company Overview
null
Management Team
| Vikas Sinha Chief Executive Officer |
| Ann Leen, PhD Chief Scientific Officer |
